The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans

Human Psychopharmacology

Volumn 19, Issue 7, 2004, Pages 457-465

  Lu, Kristy ^a   Gray, Marcus A ^a   Oliver, Chris ^b   Liley, David T ^a   Harrison, Ben J ^a   Bartholomeusz, Cali F ^a   Phan, K Luan ^c   Nathan, Pradeep J ^a  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b Blackmore's Ltd   (Australia)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Alprazolam; Anticipatory anxiety; Anxiety; Anxiety models; Anxiolytic; Benzodiazepine; GABA; L theanine

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; PLACEBO; SUNTHEANINE; THEANINE; UNCLASSIFIED DRUG;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; EVIDENCE BASED MEDICINE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYPERTHERMIA; HYPOTHERMIA; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REST; SELF REPORT; STANDARD; STATISTICAL SIGNIFICANCE; STOMACH DISEASE; TRANQUILIZING ACTIVITY; VISUAL ANALOG SCALE; VISUAL IMPAIRMENT; VOLUNTEER; XEROSTOMIA;

ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANXIETY; DOUBLE-BLIND METHOD; FEMALE; GLUTAMATES; HUMANS; MALE;

EID: 5744222751     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.611     Document Type: Article

References (66)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
2. Baas JM, Grillon C, Brocker KBE, et al. 2002. Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology (Berl) 161: 233-247.
3. Barlow DH, Chorpita BF, Turovsky J. 1996. Fear, panic, anxiety, and disorders of emotion. Nebraska Symp Motiv 43: 251-328.
4. Beck AT, Steer RA. 1987. Beck Anxiety Inventory: Manual The Psychological Corporation: San Antonio, TX.
5. Beck AT, Steer RA, Brown GK. 1996. Manual for Beck Depression Inventory-II. The Psychological Corporation: San Antonio, TX.
6. 2-induced panic attacks: a twin study. Am J Psychiatry 155: 1184-1188.
7. Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S. 1995. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry 152: 1180-1184.
8. Bitsios P, Philpott A, Langley RW, Bradshaw CM, Szabadi E. 1999. Comparison of the effects of diazepam on the fear-potentiated startle reflex and the fear-inhibited light reflex in man. J Psychopharmacol 13: 226-234.
9. Bond A, Lader M. 1974. The use of analogue scales in rating subjective feelings. Br J Med Psychol 80: 1-46.
10. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. 2002. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52: 126-135.
11. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. 1995. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 38: 742-746.
12. Casimir J, Jadot J, Renard M. 1960. Separation and characterisation of N-ethyl-δ-glutamine in Xerocomus badius (Boletus ladius). Biochem Biophys Acta 39: 462-468.
13. Charney DS. 2003. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand 108(Suppl. 417 : 38-50.
14. Chua P, Kram M, Toni I, Passingham R, Dolan R. 1999. A functional anatomy of anticipatory anxiety. Neuroimage 9: 563-571.
15. Davis M. 1984. The mammalian startle response. In Neural Mechanisms of Startle Behaviour, Eaton RC (ed.). Plenum Press: New York; 287-351.
16. de Montigny C. 1989. Cholecystokinin tetrapeptide induces panic like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiat 46: 511-517.
17. Deakin JFW, Graeff FB. 1991. 5-HT and mechanisms of defense. J Psychopharmacol 5: 305-315.
18. Fawcett JA, Kravitz HM. 1982. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacotherapy 2 243-254.
19. Graeff FG. 2002. On serotonin and experimental anxiety. Psychopharmacology 157: 256-262.
20. Graeff FG. 2003. Pharmacology of human experimental anxiety. Braz J Med Biol Res 36: 421-432.
21. Graeff FG, Zuardi AW, Giglio JS, Lima Filho EC, Karniol IG. 1985. Effect of metergoline on human anxiety. Psychopharmacology 86: 334-338.
22. Gray M, Kemp AH, Silberstein RB, Nathan PJ. 2002. Neurophysiology and psychopharmacology of anticipatory anxiety. Program No. 472.4. 2002 Abstract Viewer/Itinerary Planner. Society for Neuroscience: Washington, DC.
23. Gray MA, Kemp AH, Silberstein RB, Nathan PJ. 2003. Cortical neurophysiology of anticipatory anxiety: an investigation utilizing steady state probe topography (SSPT). Neuroimage 20: 975-986.
24. Grillon C, Ameli R. 2001. Conditioned inhibition of fear-potentiated startle and skin conductance in humans. Psychopharmacology 38: 807-815.
25. Grillon C, Ameli R, Foot M, Davis M. 1993a. Fear-potentiated startle: relationship to the level of state/trait anxiety in healthy subjects. Biol Psychiatry 33: 566-574.
26. Grillon C, Ameli R, Merikangas K, Woods SW, Davis M. 1993b. Measuring the time course of anticipatory anxiety using the fear-potentiated startle reflex. Psychophysiology 30: 340-346.
27. Grillon C, Ameli R, Woods SW, Merikangas K, Davis M. 1991. Fear-potentiated startle in humans: effects of anticipatory anxiety on the acoustic blink reflex. Psychophysiology 26: 588-594.
28. Guimaraes FS, Kohem CL, Gus G, et al. 1989. A simple simulated public speaking test for evaluating anxiolytic drugs. Braz J Med Biol Res 22: 1083-1089.
29. Hellewell JS, Guimaraes FS, Wang M, Deakin JF. 1999. Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans. J Psychopharmacol 13: 122-127.
30. Hetem LA, De Souza CJ, Guimaraes AW, Graeff FG. 1996. Effect of D-fenfluramine on human experimental anxiety. Psychopharmacology 127: 276-282.
31. Ito K, Nagato Y, Aoi N, et al. 1998. Effects of L-theanine on the release of alpha-brain waves in human volunteers. Nippon Nogeikagaku Kaishi 72: 153-157.
32. Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J. 1999. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry 45: 872-882.
33. Juneja LR, Chu D, Okubo T, Nagato Y, Yokogoshi H. 1999. L-Theanine, a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci Technol 10: 199-204.
34. Kakuda T. 2002. Neuroprotective effects of the green tea compounds theanine and catechins. Biol Pharm Bull 25: 1513-1518.
35. Kakuda T, Yanase H, Utsunomiya K, Nozawa A, Unno T, Kataoka K. 2000. Protective effect of δ-glutamylethylamide (theanine) on ischemic delayed neural death in gerbils. Neurosci Lett 289: 189-192.
36. Kent JM, Mathew SJ, Gorman JM. 2002. Molecular targets in the treatment of anxiety. Biol Psychiatry 52: 1008-1030.
37. Kimura R, Murata T. 1971. Influence of alkylamides of glutamic acid and related compounds on the central nervous system I. Central depressant effect of theanine. Chem Pharm Bull 19: 1257-1261.
38. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. 1998. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 136: 357-366.
39. Leite JR, Seabra M de L, Sartori VA, Andreatini R. 1999. The video recorded Stroop colour-word test as a new model of experimentally induced anxiety. Prog Neuropsychopharmacol Biol Psychiatry 23 809-822.
40. Lu K, Gray M, Oliver C, Nathan PJ. 2004. The neuropharmacology of L-theanine. J Herbal Pharmacotherapy. (in press).
41. Lydiard RB, Ballenger JC, Rickels K. 1997. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry 58(Suppl.): 11-18.
42. McNair DM, Frankenthaler LM, Czerlinsky T, White TW, Sasson S, Fisher S. 1982. Simulated public speaking as a model of clinical anxiety. Psychopharmacology 77: 7-10.
43. Millan MJ. 2003. The neurobiology and control of anxious states. Prog Neurobiol 70: 83-244.
44. Nakano S, Gillespie HK, Hollister LE. 1978. A model for evaluation of antianxiety drugs with the use of experimentally induced stress: comparison of nabilone and diazepam. Clin Pharmacol Ther 23: 54-62.
45. Palma SM, Guimaraes FS, Zuardi AW. 1994. Anxiety induced by simulated public speaking and stroop colour word test in healthy subjects: effects of different trait-anxiety levels. Braz J Med Biol Res 27: 2895-2902.
46. Patrick CJ, Berthot BD, Moore JD. 1996. Diazepam blocks fear-potentiated startle in humans. J Abnorm Psychol 105: 89-96.
47. 15O] water and PET. J Anxiety Disord 16: 247-258.
48. Reiman EM, Fusselman MJ, Fox PT, Raichle ME. 1989. Neuroanatomical correlates of anticipatory anxiety. Science 243 1071-1074.
49. Riba J, Rodriguez-Fornells A, Urbano G, Monte A, Antonijoan R, Barbanoj MJ. 2001. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study. Psychopharmacology 157: 358-367.
50. Sadzuka Y, Sugiyama T, Suzuki T, Sonobe T. 2001. Enhancement of the activity of doxorubicin by inhibition of glutamate transporter. Toxicol Lett 123: 159-167.
51. Sakato Y. 1949. The chemical constituents of tea; III. A new amide theanine. Nippon Nogeikagaku Kaishi 23: 262-267.
52. Sheikh JI, Swales PJ. 1999. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine and placebo. Int J Psychiatry Med 29: 91-95.
53. Silva M, Hetem LB, Guimaraes FS, Graeff FG. 2001. Opposite effects of nefazodone in two human models of anxiety. Psychopharmacology (Berl) 156: 454-460.
54. Simpson JR, Drevets WC, Snyder AZ, et al. 2001. Emotion-induced changes in human medial prefrontal cortex: II. During anticipatory anxiety. PNAS 98: 688-693.
55. Somogyi P, Hodgson AJ, Smith AD, Nunzi MG, Gorio A, Wu JY. 1984. Different populations of GABA-ergic neurons in the visual cortex and hippocampus of cat contain somatostatin or cholecystokinin-immunoreactive material. J Neurosci 4: 2590-2603.
56. Spielberger CD, Gorsuch RL, Lushene RE. 1970. Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press: Palo Alto, CA.
57. Stewart R, Devous MD, Rush AJ, et al. 1988. Cerebral blood flow changes during sodium lactate induced panic attacks. Am J Psychiatry 145: 442-449.
58. Terashima T, Takido J, Yokogoshi H. 1999. Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine. Biosci Biotech Biochem 63: 615-618.
59. Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M. 2002. Cerebral blood flow during anticipatory of public speaking in social phobia: a PET study. Biol Psychiatry 52: 1113-1119.
60. Tulen JH, Moleman P, Boomsma F, van Steenis HG, van den Heuij VJ. 1991. Dose-dependent effects of intravenous lorazepam on cardiovascular activity, plasma catecholamines and psychological function during rest and mental stress. Psychopharmacology 105: 77-83.
61. Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T. 1998a. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 23 667-673.
62. Yokogoshi H, Mochizuki M, Saitoh K. 1998b. Theanine-induced reduction of brain serotonin concentration in rats. Biosci Biotech Biochem 62: 816-817.
63. Zedkova L, Coupland NJ, Man GC, Dinsa G, Sanghera G. 2003. Panic-related responses to pentagastrin, flumazenil, and thyrotropin-releasing hormone in healthy volunteers. Depress Anxiety 17: 78-87.
64. Zuardi AW, Cosme RA, Graeff FG, Duimaraes FS. 1993. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82-88.
65. Zwanzger P, Eser D, Aicher S, et al. 2003a. Effects of alprazolam on cholecystokinin-tetrapeptide (CCK-4) induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 28: 979-984.
66. Zwanzger P, Jarry H, Eser D, et al. 2003b. Plasma gamma-aminobutyric-acid (GABA) levels in cholecystokinin-tetrapeptide (CCK-4) induced anxiety. J Neural Transm 110: 313-316.